Eli Lilly To Explore MiNA's Small Activating RNA Technology
Milestones Could Total More Than $1bn
Advances in small activating RNAs, pioneered by MiNA Therapeutics, have caught the eye of Eli Lilly, and could be the next platform to exploit gene control mechanisms to produce a new therapeutic modality.
